Early Safety Monitoring of COVID-19 Vaccines in Healthcare Workers
Joon Young Song, Hee Jin Cheong, Sung Ran Kim, Sung Eun Lee, Su Hyun Kim, Ji Yun Noh, Young Kyung Yoon, Won Suk Choi, Dae Won Park, Jang Wook Sohn, Woo Joo Kim, Min Ja Kim
Abstract
Hospital-based surveillance for adverse events was conducted on healthcare workers after they received the first dose of coronavirus disease 2019 (COVID-19) vaccine. Among the two new platform vaccines (messenger RNA- and adenoviral vector-based vaccines), the rates of systemic adverse events were significantly higher among adenovirus-vectored vaccine recipients. Fatigue (87.6% vs. 53.8%), myalgia (80.8% vs. 50.0%), headache (72.0% vs. 28.8%), and fever (≥ 38.0°C, 38.7% vs. 0%) were the most common adverse events among adenovirus-vectored vaccine recipients, but most symptoms resolved within 2 days. Both types of COVID-19 vaccines were generally safe, and serious adverse events rarely occurred.